Last update :
03/05/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Fluorouracil  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Acoflut Mexico
Adrucil United States of America
Eurofluor Germany
Fivocil India
Fivoflu India, Mexico
Fluorouracil Austria, Belgium, Brazil, Canada, Denmark, Finland, Great Britain, Greece, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Republic of South Africa, Serbia, Spain, Switzerland, Turkey, United States of America
Fluorouracile France
Flurablastin Denmark, Finland, Norway, Sweden
Fluracedyl Belgium, Luxembourg, Malaysia, Netherlands
Fluroblastin Republic of South Africa
Fluroblastine Belgium
Flurox Mexico
Neofluor Germany
Neoflur Egypt
Oncofu Argentina
Ribofluor Germany
Triosules Argentina
Stability of mixtures   Injection   Stability of mixtures : Fluorouracil     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Sodium chloride 0,9% 1 mg/ml
Injection   Fluorouracil   
Injection   Granisetron hydrochloride 0,5 mg/ml
20°C-23°C
4 Hour
Protect from light 57
Level of evidence A+
Glass Glucose 5% 0,08 mg/ml
Injection   Fluorouracil   
Injection   Palonosetron hydrochloride 26 µg/ml
25°C
4 Hour
Light 2009
Level of evidence A+
Polyvinyl chloride NaCl 0,9% or Glucose 5% 1 & 16 mg/ml
Injection   Fluorouracil   
Injection   Hydromorphone hydrochloride 0,5 mg/ml
-20°C
35 Day
Protect from light 513
Level of evidence A+
Polyvinyl chloride NaCl 0,9% or Glucose 5% 16 mg/ml
Injection   Fluorouracil   
Injection   Hydromorphone hydrochloride 0,5 mg/ml
23°C
7 Day
Not specified 513
Level of evidence A+
Polyvinyl chloride NaCl 0,9% or Glucose 5% 1 mg/ml
Injection   Fluorouracil   
Injection   Hydromorphone hydrochloride 0,5 mg/ml
23°C
35 Day
Not specified 513
Level of evidence A+
Polyvinyl chloride NaCl 0,9% or Glucose 5% 16 mg/ml
Injection   Fluorouracil   
Injection   Hydromorphone hydrochloride 0,5 mg/ml
32°C
3 Day
Not specified 513
Level of evidence A+
Polyvinyl chloride NaCl 0,9% or Glucose 5% 1 mg/ml
Injection   Fluorouracil   
Injection   Hydromorphone hydrochloride 0,5 mg/ml
32°C
7 Day
Not specified 513
Level of evidence A+
Polyvinyl chloride NaCl 0,9% or Glucose 5% 1 & 16 mg/ml
Injection   Fluorouracil   
Injection   Hydromorphone hydrochloride 0,5 mg/ml
4°C
35 Day
Protect from light 513
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 1 & 2 mg/ml
Injection   Fluorouracil   
Injection   Mannitol 200 mg/ml
25°C
24 Hour
Light 411
Level of evidence C+
Polypropylen Syringe None 24 mg/ml
Injection   Fluorouracil   
Injection   Heparin sodium 960 UI/ml
37°C
7 Day
Not specified 163
Level of evidence B
Polypropylen Syringe None 24 mg/ml
Injection   Fluorouracil   
Injection   Heparin sodium 960 UI/ml
4°C
14 Day
Protect from light 163
Level of evidence B
  Mentions Légales